@usob, Ramads assessment if echo through the kitchen sink to MTIA to fund echo.That they are still on the fence if they can develop a CGM that works. MtIA had 4 months to review the components of the new generation CGM. Ramad believes that MTIA has asked for outside opinions from experts in the medical device field if a workable CGM is feasable from the technology they received. They might have received back conflicting reports and are hesitant to fund. That is perhaps why they asked for additional info from Echo. The MTIA investors do not want to put in any additional money unless they are almost 100% sure or convinced they will have a workable CGM that would meet the standards of the CFDA. A major decision by MTIA is pending to go forward or take their losses. If MTIA goes forward with funding it would give somewhat creditability that they will prevail in a workable CGM by end of 2017 and the shareholders can breathe a sigh of relief that their investment will be rewarded handsomely.
Note that this is Ramads opinion and none of the above at this time could be confirmed.
Market Data 
Markets 
AI
